Boston Scientific (BSX) official guidance

We now expect full year 2026 adjusted below-the-line expense to be approximately $485 million, reflecting the financing impact associated with our strategic investment in MiRus and our accelerated share repurchase agreement.

We continue to expect full year 2026 adjusted below-the-line expense to be approximately $440 million.

We expect full year 2026 adjusted below-the-line expense to be approximately $440 million.

Under current legislation, including enacted laws and issued guidance, we now expect a full year 2026 adjusted tax rate of approximately 11.5%.

Under current legislation, including enacted laws and issued guidance, we now expect a full year 2026 adjusted tax rate of approximately 12.0%.

Under current legislation, including enacted laws and issued guidance, we forecast a full-year 2026 adjusted tax rate of approximately 12.5%.

The company now estimates adjusted EPS, excluding certain charges (credits), of $3.16 to $3.18.

Turning to our outlook, we now expect the second half to be more pressured than we originally anticipated. To that end, we are updating our full year 2026 guidance for organic revenue of 5%-6% with our full year adjusted EPS now at $3.28-$3.32, representing growth of 7%-8%.

The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.

Our second quarter 2026 adjusted EPS guide is $0.82-$0.84, and we now expect our full-year adjusted EPS to be $3.34-$3.41, representing growth of 9%-11%.

The company now estimates adjusted EPS, excluding certain charges (credits), of $3.34 to $3.41.

We expect full-year 2026 adjusted earnings per share to be in a range of $3.43-$3.49, representing growth of 12%-14% versus 2025, including an approximate 3-cent headwind from foreign exchange.

The company estimates adjusted EPS, excluding certain charges (credits), of $3.43 to $3.49.

The company estimates adjusted EPS, excluding certain charges (credits), of $0.77 to $0.79.

We now expect full year 2026 free cash flow to be approximately $3.8 billion.

We now expect full year 2026 free cash flow to be approximately $4 billion.

For 2026, we expect full-year free cash flow to be approximately $4.2 billion, and we continue to target free cash flow conversion in the range of 70%-80% over the long-range plan.

We expect full year 2026 adjusted gross margin to be below full year 2025, reflecting a less favorable product mix than previously anticipated, primarily driven by our lower sales outlook for WATCHMAN and electrophysiology.

We now expect full year 2026 adjusted gross margin to be slightly below full year 2025, largely driven by lower than expected product mix benefit and incremental investments in our global supply chain and quality systems.

In 2026, we anticipate full year adjusted gross margin to be roughly in line with full year 2025, as we expect favorable product mix to be largely offset by investments in our global supply chain and the annualization of tariffs.

Turning to our outlook, we now expect the second half to be more pressured than we originally anticipated. To that end, we are updating our full year 2026 guidance for organic revenue of 5%-6% with our full year adjusted EPS now at $3.28-$3.32, representing growth of 7%-8%.

Based on current rates, we expect full year 2026 operational and organic growth to be in a range of 10%-11%.

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis.

We now expect full year 2026 reported revenue growth to be in a range of 5.5%-6.5% versus 2025.

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis.

We now expect full year 2026 reported revenue growth to be in a range of 7.0%-8.5% versus 2025, excluding an approximate 50 basis points tailwind from foreign exchange based on current rates.

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an organic basis.

We expect full year 2026 reported revenue growth to be in a range of 10.5%-11.5% versus 2025, excluding an approximate 50 basis point tailwind from foreign exchange.

The company estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis.

The company estimates net sales to decline in the fourth quarter of 2026, versus the prior year period, by approximately (3.0) to (1.0) percent on a reported and organic basis.

Excluding an approximate 50 basis point tailwind from foreign exchange based on current rates, we expect full year 2026 operational and organic growth to be in a range of 5%-6%.

We expect full year 2026 operational and organic growth to be in a range of 6.5%-8.0%.

Based on current rates, we expect full year 2026 operational and organic growth to be in a range of 10%-11%.

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis.

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an organic basis.

The company estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis.

The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.